Skip to main content
ABSTRACT & COMMENTARY

Predicting the Tolerability of Sacubitril/Valsartan in Advanced Heart Failure

An analysis of the sacubitril/valsartan run-in period for chronic, advanced heart failure patients showed 18% could not tolerate the lowest dose, usually because of hypotension or renal dysfunction. Investigators identified six predictors of non-tolerance, which may help clinicians choose the best candidates.